Enliven Therapeutics Inc (ELVN): A Technical Analysis

PSX

ELVN has 36-month beta value of 1.08. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for ELVN is 28.89M, and currently, short sellers hold a 21.13% ratio of that float. The average trading volume of ELVN on October 11, 2024 was 241.61K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

ELVN) stock’s latest price update

The stock price of Enliven Therapeutics Inc (NASDAQ: ELVN) has dropped by -4.40 compared to previous close of 28.21. Despite this, the company has seen a gain of 5.72% in its stock price over the last five trading days. globenewswire.com reported 2024-09-28 that Updated Phase 1 data presented at ESH-iCMLf 26 th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their CML (NCT05304377) at the European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference.

ELVN’s Market Performance

Enliven Therapeutics Inc (ELVN) has seen a 5.72% rise in stock performance for the week, with a 16.91% gain in the past month and a 9.01% surge in the past quarter. The volatility ratio for the week is 5.53%, and the volatility levels for the past 30 days are at 5.50% for ELVN. The simple moving average for the past 20 days is 9.01% for ELVN’s stock, with a 34.28% simple moving average for the past 200 days.

Analysts’ Opinion of ELVN

Many brokerage firms have already submitted their reports for ELVN stocks, with H.C. Wainwright repeating the rating for ELVN by listing it as a “Buy.” The predicted price for ELVN in the upcoming period, according to H.C. Wainwright is $37 based on the research report published on September 09, 2024 of the current year 2024.

Robert W. Baird, on the other hand, stated in their research note that they expect to see ELVN reach a price target of $32. The rating they have provided for ELVN stocks is “Outperform” according to the report published on June 11th, 2024.

Mizuho gave a rating of “Buy” to ELVN, setting the target price at $34 in the report published on April 09th of the current year.

ELVN Trading at 15.26% from the 50-Day Moving Average

After a stumble in the market that brought ELVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.77% of loss for the given period.

Volatility was left at 5.50%, however, over the last 30 days, the volatility rate increased by 5.53%, as shares surge +20.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.24% upper at present.

During the last 5 trading sessions, ELVN rose by +5.72%, which changed the moving average for the period of 200-days by +81.62% in comparison to the 20-day moving average, which settled at $24.74. In addition, Enliven Therapeutics Inc saw 94.87% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ELVN starting from Lyssikatos Joseph P, who sale 37,878 shares at the price of $28.16 back on Oct 09 ’24. After this action, Lyssikatos Joseph P now owns 1,016,035 shares of Enliven Therapeutics Inc, valued at $1,066,561 using the latest closing price.

Lyssikatos Joseph P, the CHIEF SCIENTIFIC OFFICER of Enliven Therapeutics Inc, sale 13,267 shares at $27.97 during a trade that took place back on Oct 08 ’24, which means that Lyssikatos Joseph P is holding 1,053,913 shares at $371,024 based on the most recent closing price.

Stock Fundamentals for ELVN

Current profitability levels for the company are sitting at:

  • -221.74 for the present operating margin
  • 0.29 for the gross margin

The net margin for Enliven Therapeutics Inc stands at -188.24. The total capital return value is set at -0.32. Equity return is now at value -28.37, with -26.91 for asset returns.

Based on Enliven Therapeutics Inc (ELVN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -427.05. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -57.6.

Currently, EBITDA for the company is -81.93 million with net debt to EBITDA at 0.99. When we switch over and look at the enterprise to sales, we see a ratio of 2675.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.39.

Conclusion

To put it simply, Enliven Therapeutics Inc (ELVN) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts